CANVAS Programme: the effects of Canagliflozin on uric acid and gout in patients with type 2 diabetes


Sodium glucose co-transporter 2 ( SGLT2 ) inhibitors reduce serum urate levels. In a post hoc analysis researchers have investigated the effect of Canagliflozin ( Invokana ) compared to placebo on gout in the CANagliflozin cardioVascular Assessment Study ( CANVAS ) Program.

The CANVAS Program randomly assigned 10,142 participants with type 2 diabetes to Canagliflozin or placebo.
Patients with an adverse event attributed to gout or the need for commencement of a drug for gout were identified and the effects of Canagliflozin compared to placebo were estimated by calculating the hazard ratio ( HR ) and 95% confidence interval ( 95% CI ).

Mean serum urate levels at baseline were 348.2 ( standard deviation 94.3 ) micromol/L in the Canagliflozin group and 349.8 ( 97.1 ) micromol/L in the placebo group.

Serum urate levels were on average 23.3 micromol/L ( 95% CI: -25.4 to -21.3 ) lower in those treated with Canagliflozin compared to placebo during follow-up.

There were 70 individuals who reported an episode of gout and 147 who required commencement of a drug for gout.

The occurrence of gout or the need for treatment for gout was lower in those treated with Canagliflozin compared to placebo ( HR 0.52 95% CI: 0.38 to 0.69 ).

The separate HR for the effect on the risk of gout was 0.58 ( 95% CI: 0.36 to 0.94 ) and for the effect on the need for treatment for gout was 0.52 ( 95% CI: 0.38 to 0.72 ).

In conclusion, Canagliflozin has reduced serum urate levels and the risk of adverse events attributed to gout. ( Xagena )

Source: 55th Annual Meeting of the European Association for the Study of Diabetes ( EASD ), 2019

XagenaMedicine_2019



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect:...


SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...


New data from a sub-analysis of the landmark phase III DAPA-HF ( Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure...


Chronic kidney disease ( CKD ) risk is elevated in patients with type 2 diabetes mellitus ( T2DM ). Disease...


The FDA ( U.S. Food and Drug Administration ) has approved Qinlock ( Ripretinib ) tablets as the first new...


The FDA ( U.S. Food and Drug Administration ) has approved Tabrecta ( Capmatinib ) for the treatment of adult...


The objective of a cohort study was to assess the association between use of sodium-glucose co-transporter 2 ( SGLT2 )...


The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple...


In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor,...